Campath alemtuzumab humanized monoclonal antibody against CD52 regulatory update

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 14-1 to recommend accelerated approval of the partners' Campath

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE